产品详情
Targets
Target | Value |
---|---|
FLT1 | IC50: 8nM |
KDR | IC50: 9nM |
CSF-1R | IC50: 15nM |
LCK | IC50: 22nM |
C-Raf | IC50: 41nM |
Kit | IC50: 80nM |
FLT3 | IC50: 1.303μM |
PDGFRα | IC50: 3.408μM |
Abl | IC50: 4.738μM |
PDGFRβ | IC50: 6.9μM |
EGFR | IC50: >10μM |
AuroraA | IC50: >10μM |
Axl | IC50: >10μM |
CDK2/CyclinA | IC50: >10μM |
IKKβ | IC50: >10μM |
MEK1 | IC50: >10μM |
PDPK1 | IC50: >10μM |
PKBβ | IC50: >10μM |
Tie-2 | IC50: >10μM |
In vitro (25°C) | DMSO | 85 mg/mL (191.68 mM) | |
Water | Insoluble | ||
Ethanol | 3 mg/mL | ||
In vivo | 30% PEG400+0.5% Tween80+5% propylene glycol | 4 mg/mL | |
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.1 mM | 22.55 mL | 112.76 mL | 225.53 mL |
0.5 mM | 4.51 mL | 22.55 mL | 45.11 mL |
1 mM | 2.26 mL | 11.28 mL | 22.55 mL |
5 mM | 0.45 mL | 2.26 mL | 4.51 mL |
*The above data is based on the productmolecular weight 443.4 . Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
目录号 | A10679 |
---|---|
作用机制 | Inhibitor (抑制剂) |
M. Wt | 443.4 |
Formula | C22H16F3N3O2S |
Purity | >99% |
Storage | Store lyophilized at -20ºC, keep desiccated. |
CAS No. | 728033-96-3 |
Synonyms | OSI930 |
SMILES | C1=CC=C2C(=C1)C(=CC=N2)CNC3=C(SC=C3)C(=O)NC4=CC=C(C=C4)OC(F)(F)F |
产品标签
Product Questions
Product Questions
Pazopanib (GW-786034)
Pazopanib (GW-786034)是VEGFR-1,VEGFR-2,VEGFR-3,PDGFR-a/β和c-kit的有效且选择性的多靶点酪氨酸激酶抑制剂,可阻…
Brivanib (BMS-540215)
Brivanib (BMS-540215)是一种VEGFR-2抑制剂,IC50为25 nM,Ki为26 nM。
Imatinib (Gleevec)
Imatinib (Gleevec)是一种多靶点酪氨酸激酶抑制剂,抑制v-Abl、c-Kit和PDGFR的IC50分别为0.6,0.1和0.1 μM。
Raf265 derivative
Raf265 derivative是Raf265的衍生物,Raf265是一种口服,高度选择性的RAF和VEGFR激酶抑制剂,IC50为5至10μM。
TPT-260 (Dihydrochloride)
TPT-260是噻吩硫脲衍生物。
Bibf1120 (Nintedanib)
Bibf1120 (Nintedanib)是一种新型的三联血管激酶抑制剂,可同时抑制三种生长因子受体:VEGFR,PDGF和FGFR。